A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Impact of Low Doses of Nilotinib (Tasigna®) on Safety, Biomarkers and Clinical Outcomes in Subjects With Mild to Moderate Alzheimer's Disease
NCT02947893 · COMPLETED · Phase 2
We track 1 ClinicalTrials.gov studies led by Georgetown University. The portfolio skews toward Phase 2 (1 trials).
1 clinical trials sponsored by Georgetown University.
| Phase | Trials | Distribution |
|---|---|---|
| Phase 2 | 1 | 100% |
Georgetown University currently sponsors 1 clinical trials tracked on ReadTheTrial. These span Phase 2.
Georgetown University conducts research across multiple therapeutic areas. Browse the trial listings for details.
Check the trial listings below for current recruitment status. Trial recruitment status can change frequently.